Ruben A. Mesa, MD

Ruben A. Mesa, MD, discusses the approval of fedratinib in myelofibrosis and other JAK inhibitors in the treatment pipeline.

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the FDA approval of fedratinib (Inrebic) in myelofibrosis.

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses how community oncologists can incorporate the NCCN Guideline for Myeloproliferative Neoplasms (MPNs) into clinical practice.

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs).

Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN guidelines for treatment of patients with myeloproliferative neoplasms (MPNs).

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses advancements in polycythemia vera (PV).

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses the intended patient population with myelofibrosis and low platelet counts for pacritinib.

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses PERSIST-1, a phase III study which examined pacribitinib as a treatment of myelofibrosis.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the mechanism of action of ruxolitinib in chronic myeloid leukemia.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, describes three phase II and phase III trials in myelofibrosis.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the use of JAK2 inhibitors in patients with myelofibrosis.

Dr. Ruben Mesa, from Mayo Clinic, Arizona, Discusses the COMFORT Ruxolitinib Trials

Dr. Ruben Mesa from the Mayo Clinic in Arizona Discusses JAK Inhibitors for Myelofibrosis